Active Ingredient: PEMIGATINIB
Pemigatinib is a selective FGFR inhibitor indicated for cholangiocarcinoma that demonstrates no clinically significant effect on cardiac repolarization or QTc intervals. In the FIGHT-101 first-in-human study of 113 patients with advanced malignancies, categorical analysis of Fridericia-corrected QT intervals (QTcF) and plasma concentration-QTc modeling showed no dose- or concentration-dependent repolarization delay. Furthermore, pemigatinib exhibited no clinically meaningful changes in heart rate, PR interval, or QRS duration.
https://doi.org/10.1002/prp2.906